NEJM· @NEJM · X·· 25 天前精选AI 评分75
AI 导读
OCIN 2026 会议公布的 MILD-MT 试验结果显示,轻症大血管闭塞卒中患者接受血管内治疗联合药物管理后,90 天良好功能结局比例为 69.4%,单纯药物管理组为 50.0%。完整结果见 https://nej.md/4hWstFc。
推荐理由
MILD-MT 试验在 OCIN 2026 公布,轻症大血管闭塞患者接受血管内治疗联合药物管理的 90 天良好功能结局比例高于单纯药物管理。
正文
Presented at the OCIN 2026 Conference:
Among patients with mild stroke from large-vessel occlusion, 69.4% had a favorable functional outcome at 90 days with endovascular therapy plus medical management, as compared with 50.0% with medical management alone. Full MILD-MT trial results: https://nej.md/4hWstFc
来源:NEJM · x.com